Affordable health care and improved wellness

There’s A New And Better Way To Get AFFORDABLE HEALTH CARE! For Just $19.95/Month You Get 24/7 UNLIMITED ACCESS To U.S. Licensed Doctors Who Will Diagnose And Treat Common Conditions Over Your Phone,Computer Or Tablet With NO CO-PAYS Or Deductibles. And (If Needed) Medication Is Prescribed And Sent To Your Preferred Pharmacy. With NO CO-PAY’S Or DEDUCTIBLES Join Today! https://goo.gl/Y12enu Read More …

Profectus Biotech and Medisun Medical Group new joint venture in Hong Kong

The famous American vaccine company Profectus settled in Hong Kong

First recommend HPV cervical cancer treatment vaccine

BALTIMORE, MARYLAND, USA and HONG KONG, April 20, 2018

Profectus Biotech and Medisun Medical Group today announced the opening of a new joint venture in Hong Kong. The primary mission of the new company, ProMed BioSciences, Ltd., is to establish a leading vaccine company focused on the development of preventive and therapeutic vaccines for infectious diseases and cancer. The joint venture will leverage Profectus’ vaccine development expertise, clinically proven vaccine platform technology and a developing vaccine product line, in line with Medisun’s expertise, established clinical network and market access capabilities, expected in the second half of 2018 to put into operation.

The company’s first product development program will focus on the development, production and commercial application of prophylactic and therapeutic vaccines for HPV (human papillomavirus)-related lesions and cervical cancer [based on PBSVax® technology developed by Profectus]. ProMed BioSciences also plans to develop and treat hepatitis C virus (HCV), hepatitis B virus (HBV), herpes simplex virus (HSV), respiratory syncytial virus (RSV), and human immunodeficiency virus (HIV). Chikungunya and Zika, as well as personalized vaccines to treat cancer. The joint venture is expected to launch new vaccines in their respective markets, which will help promote the development of new vaccines, but ultimately the goal is to benefit patients around the world.

Mr. Jeffery Meshulam (first from left), President of Profectus Biotechnology, Mr. Terry Lierman (second from left), Chairman of Medivh Medical Group, and Mr. Danny Wong (fourth from right), founder and executive chairman of Medisun Medical Group, at Profectus ,USA.

– Long-term strategic cooperation to address the huge demand for prevention and treatment of infectious diseases and cancer in Asia

-Profectus’ expertise in vaccine development and platform technology, combined with Medisun’s localized expertise and experience, to establish a leading Hong Kong vaccine company focused on serving Asia

“This strategic cooperation will help establish Profectus’ business in Hong Kong and China. Through close cooperation with Medisun, we can assist Hong Kong and China to develop advanced vaccine technology to help prevent and treat Asian patients. Mr. Jeffrey Meshulam, President of Profectus, said, “We are pleased to be able to work with recognized local partners to achieve the highest standards of scientific research and development integration and medical services.”

“This collaboration will help Profectus and Medisun to jointly produce life-saving vaccines for infectious diseases and cancer, and address the huge medical needs that have not been met in Hong Kong, China and Asia.” Mr. Danny Wong, founder and executive chairman of Medisun Medical Group, said “ProMed BioSciences will leverage Profectus’ expertise in vaccine development and technology, combined with Medisun’s local expertise and close links with healthcare facilities in Hong Kong and China, and government medical regulatory agencies to develop vaccines to provide leadership for Asian patients disease prevention and treatment programs.”

ProMed BioSciences will focus on the following:

• Conduct technical research in Hong Kong or China

• Conduct clinical trials in Hong Kong or China

• Promote the expansion of Medisun Medical Center

• Develop vaccines to address disease prevention needs

• leverage to maximize the expertise of both partners

Mr. Jeffery Meshulam, President of Profectus Biotechnology (first from left), Mr. Terry Lierman, Chairman of Medisun Medical Group (first from right), Mr. Danny Wong, founder and executive chairman of Medisun Medical Group (middle), at the US headquarters of  Profectus.

About ProMed BioSciences

ProMed BioSciences Limited is a joint venture between Profectus BioSciences (USA) and Medisun Medical Group (Hong Kong) in Hong Kong to develop and conduct new vaccine clinical trials and commercial applications to address infectious diseases and cancer in Asia with the huge demand for prevention and treatment.

About Medisun

Headquartered in Hong Kong, Medisun Medical Group is a professional medical investment group dedicated to the research and development and commercialization of global regenerative Medisunne products, as well as quality hospitals and treatment centers. Medisun invests extensively in the fields of regenerative and stem cell patent technology, including stem cell therapy for heart failure, stem cell therapy for liver disease, kidney disease, nervous system disease, cancer, AIDS, and immune cell therapy for a variety of cancers. Medisun and Harvard University Stem Cell Research Institute, Johns Hopkins Medical School Life Science Center, Tsinghua University and other institutions have long-term cooperation plans to jointly invest in regenerative and stem cell therapy technology, with Medisun as a cooperative business The holding entity and holds global intellectual property rights. Medisun and the University of Maryland’s Institute of Human Virology (IHV) set up a technology clinical trial and development platform for viruses and cancer. Based on the Medisun Biomedical Laboratory in Hong Kong, Radiation will jointly build medical clinics in China and Asia. The experimental resource network promotes the world’s largest clinical research and development platform for virus research and cancer treatment technology. The Medisun Reproductive Centre is located at the Proud Square in Kowloon Bay, Hong Kong. It has a 50,000 square foot stem cell GMP production base, a cancer treatment centre and an anti-aging centre. It brings together European, Japanese, American and individual Chinese experts to develop a rigorous and professional R&D process. Provides immune cell therapy and a variety of stem cell health treatments.

For more information, please visit http://www.medisun.hk/

About Profectus BioSciences

Profectus BioSciences is a clinical stage vaccine development company focused on developing new vaccines for infectious disease and cancer prevention and treatment. The Profectus vaccine is based primarily on the company’s proprietary VesiculoVax™ and DNA vaccine technology platform. By simply using the VesiculoVax™ vaccine alone, B cells can be rapidly expanded to provide protection against emerging infectious diseases that threaten public health and biodefense mechanisms, such as Ebola, Marburg, Chikungunya, Zika virus, equine encephalitis virus, and respiratory syncytial virus. When VesiculoVax™ is used as a vaccine when the immune system is launched with the best pDNA vaccine, the Vesiculo Vax™-directed vaccine expands the triggered T cells into effector cells, which are ideal for attacking virus-infected cells and cancer. Current projects using the Prime / Boost Vaccine System (PBS Vax™) strategy include hepatitis B virus (HBV), human papillomavirus (HPV), herpes simplex virus type 2 (HSV-2) and human immunodeficiency virus ( HIV). Partners and collaborators include UTMB’s Galveston National Laboratory, Yale University, University of Maryland Human Virology Institute, HIV/AIDS Vaccine Immunology Center, National Cancer Institute, National Institutes of Health AIDS Division, Bill And the Melinda Gates Foundation, the International AIDS Vaccine Initiative, the AIDS Vaccine Trial Network and the AIDS Clinical Trial Group. Profectus is funded by Cross Atlantic Capital Partners (“XACP”) in Radnor, Pennsylvania. The main investor in XACP is the Pennsylvania Public School Employees Retirement System (“PSERS”). For more information, please visit www.profectusbiosciences.com

Advair Diskus 250 50 product specifications and best places to buy it

ADVAIR DISKUS & ADVAIR HFA are prescription medications for asthma & ADVAIR DISKUS 250/50 is a prescription medicine for COPD. Learn more about ADVAIR today.

Advair Diskus and Symbicort are both maintenance inhalers and often compared—so which one is right for you? You should know that they are both used to treat asthma and COPD, but they also have several differences including active ingredients, directions for use, and insurance coverage.

If you have asthma or chronic obstructive pulmonary disease (COPD), your doctor may suggest the Advair Diskus inhaler. This is an easy and effective treatment that can be used to improve your breathing and the long term health of your lungs. Read More …

Company Implemented Multilayered Security Architecture on Managed Services Platform

ANEXIO, the leading “Desktop to Data Center” infrastructure-as-a-service company, today announced that is has been named one of the 10 best security companies in 2017 by CIO Bulletin. This recognition is due, in part, to ANEXIO’s ability to help customers securely accelerate their digital transformation by implementing a multilayered security architecture, driven by industry compliance standards, across the company’s managed services platform.

ANEXIO specializes in helping customers transition from their legacy IT environment to a more secure digital infrastructure. Companies transforming into digital enterprises typically share three characteristics:

1. Applications have become the revenue driver of their business

2. Users expect flawless experience from those applications

3. The security for these mission critical applications has become more complex

“Every day, more and more mid-market companies are becoming full-time digital enterprises,” said Tony Pompliano, ANEXIO President and CEO. “It’s an honor to receive this recognition from CIO Bulletin, but, even more importantly, it’s an honor to help our customers accelerate their digital transformation. ANEXIO is proud of the technology investments that we’ve made to help secure the experience of our digital end users against the ever-increasing security threats that all enterprises face in today’s connected world of applications, networks, data centers and hybrid clouds.”

ANEXIO understands that no two customer digital transformations are alike. Physical, logical and virtual security is woven into the fabric of ANEXIO’s offerings. The company’s phased migration process addresses the unique challenges of each customer:

1. Assessment Phase: Clarify the customer’s business objectives, understand the operational risks and then identify the migration path to the ANEXIO Cloud.

2. Decision Phase: ANEXIO experts create a comprehensive, end-to-end transition plan with special focus on security, performance, and zero downtime for the customer.

3. Implementation Phase: ANEXIO engineers work with the customer to finalize the migration schedule, provision the environment and then commence the migration to the ANEXIO cloud.

Customers interested in learning more about ANEXIO’s security portfolio or digital transformation capabilities can email info@anexio.com and request a briefing.

ABOUT ANEXIO

ANEXIO is transforming the IT industry with Desktop to Data Center solutions designed specifically for customers seeking a smooth transition from legacy IT environments to a more efficient Hybrid Cloud infrastructure. The Inc. 500 company’s Mission Critical Infrastructure strategy is anchored by eight Tier III SOC-2 certified data centers, an IT solutions center and a nationwide IP Network. ANEXIO’s offerings include colocation, networking, Cloud services, storage, disaster recovery, Managed IT and Managed VoIP. Every ANEXIO product and service is backed up by United States-based customer support. Visit www.anexio.com for more information.

Media Contact:

Amy Laukka
(919) 802-4304
alaukka@boltpr.com

SOURCE ANEXIO
Related Links

Home

The Mary C. O’Keefe Cultural Center Will Host Hurricane Harvey Benefit Show September 24th

Who knew a devastating hurricane in the Texas Gulf Coast would inspire so many communities across America to pitch-in and help? But that’s exactly what’s happening September 24th in Ocean Springs, Mississippi when “FRANK & LIZA” come to the Mary C. This strong community already knows the impact of a record-breaking storm. In 2005, Hurricane Katrina ravaged their own coastline. But today, it’s Houston and the Texas coast that urgently need the help.

Thanks to the Mary C. O’Keefe Cultural Center, the exhilarating musical tribute to “Frank Sinatra & Liza Minnelli” will come to Ocean Springs for one Sunday matinee benefiting the Hurricane Harvey Relief Fund. The show is a rapid-paced musical journey through the classic and timeless hits of Frank Sinatra and the Broadway-like song and dance spectacle that is Liza Minnelli’s trademark.

Described as “warm, witty and sexy”, the Las Vegas show features a delightful exchange of music, humor and dazzling duets between two of the most talented artists working today – Dave Halston and Suzanne Goulet. Together, “FRANK & LIZA” will not only thrill a willing audience, they will make it easy for virtually anyone to assist in the Hurricane Harvey relief effort.

Seating is limited. Tickets are available online now for $25.

About the Hurricane Harvey Relief Fund:
After receiving an overwhelming number of inquiries from citizens and companies who want to help, Houston Mayor Sylvester Turner and County Judge Ed Emmett have established the Hurricane Harvey Relief Fund that will accept tax deductible flood relief donations for victims that have been affected by the recent floods. The fund will be housed at the Greater Houston Community Foundation, a 501(c)(3) public charity.

About the Artists:

Dave Halston comes with an impressive resume – working a multitude of theatres, casinos, special events and private parties coast to coast – and in most cases, leaving the audience stunned. As one observer described it, “Dave Halston somehow casts a spell, and they always want more.” Even Barbara Sinatra was brought to tears when Dave performed for her at an exclusive private event. She called his performance “wonderful” and noted specifically the fine job Dave did with Sinatra’s signature song “My Way”.

In addition to Mrs. Sinatra, Dave has also entertained Jeanne Martin (Mrs. Dean Martin), recording artists Michael Feinstein, Steve Tyrell and Mr. Las Vegas himself, Wayne Newton, among other notables.

Suzanne Goulet was born in Montreal, Canada and has been dancing since the age of 3. She starred in “Fantastique” at the Sheraton Bal Harbour in Miami Beach, then at the Sands Casino in Atlantic City and at the Condado Plaza in San Juan, Puerto Rico. She then joined “Hooray for Hollywood” for an international tour to Spain, Switzerland and Japan. She also choreographed and danced for a show on the “Song of America” cruise ship from RCCL. After studying voice in New York City, she won the “Smirnoff Makes You A Star” competition and began her career as a tribute artist.

In 1996, Suzanne joined “Legends in Concert” at Bally’s Grand in Atlantic City. Then she followed the show to the Imperial Palace in Las Vegas where she received rave reviews and numerous awards.

Show Details:

“FRANK & LIZA”
A Musical Tribute to Frank Sinatra and Liza Minnelli
2:30PM | Sunday, September 24th, 2017
TICKETS: $25

The Mary C. O’Keefe Cultural Center of Arts and Education
1600 Government Street
Ocean Springs, Mississippi 39564
228.818.2878